Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Q24244898)

Europe PubMed Central

title

Neuraminidase inhibitors for preventing and treating influenza in healthy adults (English)

0 references

1

Tom Jefferson

0 references

author name string

Mark A Jones

2

0 references

Peter Doshi

3

0 references

Chris B Del Mar

4

0 references

Liz Dooley

5

0 references

Rokuro Hama

6

0 references

Carl J Heneghan

Cochrane Database of Systematic Reviews

7

0 references

publication date

19 July 2006

0 references

published in

0 references

cites work

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Early administration of oral oseltamivir increases the benefits of influenza treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

A change in the effectiveness of amantadine for the treatment of influenza over the 2003-2004, 2004-2005, and 2005-2006 influenza seasons in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Bird flu and pandemic flu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Neuraminidase inhibitors—the story behind the Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Developing new antiviral agents for influenza treatment: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Possible harms of oseltamivir--a call for urgent action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Antivirals for influenza in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Avian influenza A (H5N1) infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Prevention and early treatment of influenza in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Tamiflu side effects come under scrutiny

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

7 January 2021

Zanamivir treatment is equally effective for both influenza A and influenza B

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

7 January 2021

Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

7 January 2021

Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

7 January 2021

Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

7 January 2021

Human illness from avian influenza H7N3, British Columbia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

7 January 2021

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001265.PUB2

7 January 2021

10.1002/14651858.CD001265.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

3994098

3994098

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference